Understanding Uveitis: Protecting Your Vision
Understanding Uveitis
The uvea is the middle layer of the eye wall. It sits between the outer white layer (the sclera) and the inner layer (the retina). The uvea contains many blood vessels that deliver oxygen and nutrients to the eye. It is made up of three parts: the iris (the colored part of the eye), the ciliary body (a ring of tissue behind the iris that helps focus the lens), and the choroid (a thin layer of blood vessels beneath the retina).
When any part of the uvea becomes inflamed, the condition is called uveitis. The inflammation can also spread to nearby structures, including the retina and the optic nerve, causing further damage.
Uveitis is classified into four types based on which part of the eye is affected.
- Anterior uveitis affects the front of the eye, mainly the iris. This is the most common type.
- Intermediate uveitis affects the ciliary body and the vitreous (the gel that fills the middle of the eye).
- Posterior uveitis affects the choroid and the retina at the back of the eye. This type is most closely managed by retina specialists.
- Panuveitis involves inflammation throughout all parts of the uvea.
Uveitis occurs when immune cells cross the protective blood-ocular barrier and enter the eye. Normally, this barrier keeps immune cells from reaching the inside of the eye. When the barrier is disrupted, white blood cells invade the eye and cause swelling and tissue damage.
In autoimmune forms of uveitis, certain immune cells called T cells become activated and attack proteins within the eye. Recent research suggests that bacteria living in the gut may play a role in triggering this process. These activated T cells then travel through the bloodstream and enter the eye, where they cause inflammation.
Uveitis can appear suddenly or develop gradually over time. An acute episode comes on quickly and may last a few weeks. Recurrent uveitis means the inflammation returns after periods of being quiet. Chronic uveitis lasts for months or longer and may require ongoing treatment to keep the inflammation under control.
Who Is Affected and Risk Factors
Uveitis affects more people than many realize. In the United States, the cumulative incidence and prevalence from 2013 to 2023 were 212.5 and 260.8 per 100,000 persons, respectively (Pubmed, 2025). Children can also develop uveitis, with an annual prevalence of pediatric noninfectious uveitis of 11.9 cases per 100,000 patients according to the IRIS Registry (Pubmed, 2025). The condition can develop at any age but is most common in adults between 20 and 60 years old.
People with certain autoimmune diseases have a higher risk of developing uveitis. These conditions include ankylosing spondylitis (an inflammatory disease of the spine), inflammatory bowel disease, rheumatoid arthritis, lupus, sarcoidosis, and Behcet disease. A genetic marker called HLA-B27 increases the risk of acute anterior uveitis by 50% to 80% in those who carry it.
Several infections can trigger uveitis. These include herpes simplex virus, herpes zoster virus (shingles), syphilis, toxoplasmosis (a parasitic infection), tuberculosis, and Lyme disease. When an infection is the cause, treating the underlying infection is an essential part of managing the eye inflammation.
Smoking cigarettes increases the risk of uveitis. Certain medications can also trigger the condition, including bisphosphonates (drugs used to treat osteoporosis), checkpoint inhibitors (drugs used in cancer treatment), and some live vaccines. Females tend to have a higher prevalence in adult populations. Environmental factors and the composition of gut bacteria may also contribute to who develops this condition.
Signs and Symptoms
The symptoms of uveitis depend on which part of the eye is affected. Many people notice symptoms that come on suddenly and worsen over hours or days.
- Eye pain or aching
- Redness in the white of the eye
- Sensitivity to light, known as photophobia
- Blurred or decreased vision
- Floaters, which are dark spots or strands drifting across the field of vision
Certain symptoms signal a serious problem and require immediate care. If you experience sudden eye pain with redness, a rapid increase in floaters, flashes of light, a shadow or curtain across your vision, or sudden vision loss, see a retina specialist or go to the emergency room immediately. These symptoms can indicate that the inflammation is causing damage that may become permanent without prompt treatment.
Anterior uveitis often causes the most noticeable pain and redness. Intermediate and posterior uveitis may produce fewer outward signs but can cause significant floaters and blurred vision. Panuveitis may involve all of these symptoms at once. Posterior uveitis is particularly concerning because it directly affects the retina and can lead to lasting vision changes.
Diagnosis and Testing
A retina specialist will perform a thorough eye examination to look for signs of inflammation inside the eye. This includes using a slit lamp, which is a specialized microscope that provides a magnified view of the front and back of the eye. The specialist will look for inflammatory cells floating in the fluid inside the eye, protein deposits on the back of the cornea, and swelling in the retina.
Several imaging tests help a retina specialist evaluate the extent of inflammation and any complications it may have caused.
- Optical coherence tomography, or OCT, creates detailed cross-sectional images of the retina. It can detect macular edema (swelling in the center of the retina).
- Fluorescein angiography involves injecting a dye into a vein in the arm and photographing the blood vessels in the retina to check for leakage or damage.
- Ultrasound imaging may be used if inflammation makes it difficult to see the back of the eye clearly.
Because uveitis is often linked to autoimmune conditions or infections, a retina specialist may order blood tests and other laboratory work. These tests can check for markers like HLA-B27, signs of sarcoidosis, syphilis, tuberculosis, and other conditions. Identifying the underlying cause helps guide treatment decisions. In many cases, no specific cause is found. This is called idiopathic uveitis.
The Standardization of Uveitis Nomenclature (SUN) Working Group has developed classification criteria for 25 types of uveitis. This system helps retina specialists identify the specific form of uveitis accurately. More recently, machine learning tools have been applied to these criteria to improve diagnostic consistency and advance research into new treatments.
Treatment Options
Corticosteroids are the most common first treatment for uveitis. They work by quickly reducing inflammation. Depending on the type and severity of uveitis, corticosteroids may be given in several forms.
- Topical eye drops for anterior uveitis
- Periocular injections (injections around the eye) for intermediate or posterior inflammation
- Intravitreal injections (injections directly into the eye) for more severe cases
- Oral corticosteroids for widespread or bilateral inflammation
The POINT Trial demonstrated that intravitreal steroid delivery is more effective than periocular delivery for uveitic macular edema (swelling in the center of the retina caused by uveitis).
For intermediate, posterior, or panuveitis, a retina specialist may recommend a steroid implant placed inside the eye. Ozurdex (dexamethasone implant) is a biodegradable implant that releases medication over several months. Retisert (fluocinolone acetonide implant) is a longer-lasting surgical implant that can deliver medication for up to three years. These implants provide sustained treatment directly at the site of inflammation, reducing the need for frequent injections or oral medications.
When uveitis is chronic or when long-term steroid use poses risks such as cataracts or glaucoma, a retina specialist may recommend steroid-sparing medications. Methotrexate is the most commonly used option. The FAST Trial (2023) showed that methotrexate is as effective as, or more effective than, mycophenolate mofetil for uveitis, particularly for posterior uveitis and panuveitis. Mycophenolate mofetil remains another option for patients who cannot tolerate methotrexate.
For severe or treatment-resistant uveitis, biologic agents may be used. Adalimumab (Humira) was FDA-approved in June 2016 for adult noninfectious intermediate, posterior, and panuveitis. It remains the only FDA-approved systemic biologic for uveitis. Multiple adalimumab biosimilars have become available since 2023, which has helped improve access to this treatment. Research into newer biologic approaches, including IL-6 inhibition (the DOVETAIL study) and IL-35-based therapies, shows promise for future treatment options.
When uveitis is caused by an infection, treating that infection is a critical part of care. Antiviral, antibiotic, antifungal, or antiparasitic medications may be prescribed depending on the specific organism involved. In these cases, using immunosuppressive drugs without treating the infection could make the condition worse.
What to Expect
Treatment for uveitis often begins with frequent visits to monitor how well the inflammation is responding. If you are using steroid eye drops, you may start by applying them many times per day, then gradually tapering as the inflammation improves. If you receive injections or an implant, your retina specialist will schedule follow-up visits to check your response and watch for side effects.
For patients on immunosuppressive medications or biologics, regular blood tests may be needed to monitor for potential side effects. It may take several weeks to see the full effect of these medications.
Uveitis can lead to several complications if not treated promptly or if the inflammation is difficult to control.
- Cystoid macular edema, or swelling in the center of the retina, which can reduce central vision
- Cataracts, a clouding of the lens inside the eye
- Glaucoma, an increase in eye pressure that can damage the optic nerve
- Retinal detachment, where the retina separates from the back of the eye
- Permanent vision loss in severe or untreated cases
The outlook for uveitis depends on the type, the underlying cause, and how quickly treatment begins. Many people with acute anterior uveitis respond well to treatment and have a good visual outcome. Chronic and posterior forms of uveitis often require longer and more complex treatment plans. With consistent monitoring and appropriate therapy, many patients are able to maintain useful vision. Early treatment is the most important factor in preventing lasting damage.
Living With Uveitis
Living with uveitis means staying committed to regular follow-up appointments. Even when your eyes feel comfortable and your vision seems stable, inflammation can return without warning. A retina specialist will use imaging and examination to detect early signs of a flare before symptoms become noticeable. Keeping all scheduled appointments is one of the most effective ways to protect your vision long term.
Because uveitis is often connected to autoimmune or inflammatory diseases, managing your overall health is important. Working with your primary care physician, rheumatologist, or other specialists can help keep underlying conditions under control. This coordinated approach reduces the likelihood of uveitis flares. If you smoke, quitting is strongly recommended, as smoking is a known risk factor for uveitis and can worsen outcomes.
A diagnosis of uveitis can feel overwhelming, especially when it is chronic or recurrent. Vision changes can affect your ability to work, drive, and enjoy daily activities. It is important to communicate openly with your retina specialist about how the condition is affecting your life. Support groups and patient education resources from organizations such as the American Academy of Ophthalmology and the National Eye Institute can provide helpful information and connect you with others who share similar experiences.
When to See a Retina Specialist
Seek care from a retina specialist or go to the emergency room immediately if you experience any of the following symptoms: sudden eye pain with redness, a rapid increase in floaters or new floaters, flashes of light, a curtain or shadow spreading across your vision, or sudden loss of vision. These symptoms may indicate that uveitis is causing serious damage inside the eye. Delaying care can lead to permanent vision loss.
If you have been diagnosed with an autoimmune condition such as ankylosing spondylitis, sarcoidosis, inflammatory bowel disease, or Behcet disease, ask your doctor about screening for uveitis. An optometrist or primary care doctor can perform an initial evaluation, but intermediate, posterior, and panuveitis are best managed by a retina specialist who has training in treating inflammation at the back of the eye. Early referral leads to earlier treatment and better visual outcomes.
Questions and Answers
Uveitis can lead to permanent vision loss if it is not treated promptly or if the inflammation is severe and difficult to control. It accounts for approximately 10% of all blindness cases in the United States (AAO). However, with early diagnosis and proper treatment, many patients maintain useful vision for years. The key is seeking care as soon as symptoms appear and following the treatment plan recommended by your retina specialist.
Uveitis itself is not contagious. You cannot catch it from another person or pass it on through contact. In some cases, uveitis is caused by an infection that may be transmissible, such as herpes or toxoplasmosis. However, the eye inflammation that results from these infections is an immune response within your own body and is not something that spreads from person to person.
The duration of a uveitis flare depends on the type and severity. Acute anterior uveitis may resolve within a few weeks with proper treatment. Chronic forms of uveitis, particularly posterior uveitis and panuveitis, can last for months and may require ongoing medication to keep inflammation in check. Each person responds differently, so your retina specialist will tailor the treatment timeline to your specific situation.
Not everyone with uveitis needs lifelong medication. Some people experience a single episode that resolves with short-term treatment. Others have recurrent or chronic uveitis that requires long-term immunosuppressive therapy to prevent flares and protect vision. Your retina specialist will work with you to find the lowest effective level of treatment and will adjust your plan over time based on how your eyes respond.
Yes, children can develop uveitis. The annual prevalence of pediatric noninfectious uveitis in the United States is 11.9 cases per 100,000 patients (IRIS Registry, 2025). In children, uveitis is often associated with juvenile idiopathic arthritis and may develop without obvious symptoms like pain or redness. Regular eye examinations are important for children with known autoimmune conditions so that uveitis can be detected and treated before it causes vision loss.